Inhibrx, Inc.
INBX

$213.66 M
Marketcap
$14.76
Share price
Country
$-0.12
Change (1 day)
$18.95
Year High
$10.80
Year Low
Categories

Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.

marketcap

Inhibrx, Inc. (INBX) - Company Outlook



Company Outlook

Year Receivables Debt Liabilities Assets Current Assets
2023 778 K -67,783,000 264.39 M 307.89 M 295.36 M
2022 257 K -71,796,000 232.82 M 290.88 M 280.49 M
2021 878 K -60,831,000 98.07 M 150.45 M 139.11 M
2020 615 K -91,210,000 68.27 M 143.74 M 132.17 M
2019 438 K 30.19 M 120.06 M 26.49 M 15.56 M